title: Characterization of a novel active release coating to prevent biofilm implant-related infections.
abstract: Biofilm implant-related infections cost the US healthcare system billions of dollars each year. For several decades, device coatings have been developed that actively release antimicrobial compounds in an attempt to prevent these infections from developing. To date, few coatings have been put into clinical use. These have shown limited to no efficacy in clinical trials. Recent data have shown the in vitro and in vivo efficacy of a novel active release coating that may address the limitations of coatings that are used clinically. In this study, the novel active release coating was characterized to gain an understanding of the effects of combining an antimicrobial additive, cationic steroid antimicrobial-13 (CSA-13), to a medical grade polydimethylsiloxane (PDMS) material. Results indicated that the addition of CSA-13 did influence the physical properties of the PDMS, but not with adverse effects to the desired material properties. Furthermore, there was no indication of chemical reactivity. It was shown that CSA-13 was uniformly dispersed as small particles throughout the PDMS matrix. These particles were able to dissolve and elute out of the PDMS within a 30-day period. The results of this work suggested that the PDMS with CSA-13 was thermally, chemically and physically stable when used as a device coating to treat local infection and/or prevent biofilm implant-related infections from developing.
authors.affiliation: George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA. dustin.williams@utah.edu
authors.forename: Dustin L
authors.initials: DL
authors.lastname: Williams
authors.forename: Kristofer D
authors.initials: KD
authors.lastname: Sinclair
authors.forename: Sujee
authors.initials: S
authors.lastname: Jeyapalina
authors.forename: Roy D
authors.initials: RD
authors.lastname: Bloebaum
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000737:chemistry*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development*; D001860:Bone Plates / Q000009:adverse effects / Q000382:microbiology; D020099:Coated Materials, Biocompatible / Q000737:chemistry*; D004129:Dimethylpolysiloxanes / Q000737:chemistry; D006801:Humans; D008422:Materials Testing; D008855:Microscopy, Electron, Scanning; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D017550:Spectroscopy, Fourier Transform Infrared; D013256:Steroids / Q000008:administration & dosage / Q000737:chemistry; D013499:Surface Properties; D013718:Tensile Strength; D013818:Thermogravimetry
chemical_list: D000890:Anti-Infective Agents; D020099:Coated Materials, Biocompatible; D004129:Dimethylpolysiloxanes; D013256:Steroids; C521528:ceragenin CSA-13; C013830:baysilon
keywords: CSA-13; PDMS; active release; antimicrobial; characterization; coating